ARROWHEAD PHARMACEUTICALS, INC. (ARWR) research
ARROWHEAD PHARMACEUTICALS, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $62.35
- As of
Kresmion compiles this page from ARWR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-04.
As of . Source: SEC EDGAR filings for ARWR. Method and limitations.
Share the ARWR intelligence card
See the full ARWR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ARWR on one page. Preview it with sample data, then open it live with a free account.
Preview the ARWR dossierActive signals for ARWR
- highCONSENSUS_BUY
3 tracked funds increased ARWR this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +300% to ARWR (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +113% to ARWR (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +74% to ARWR (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +632% to ARWR (2026Q2)
FREE, NO ACCOUNT
Every signal on ARWR, as it fires
You are seeing 5 of 12 signals recorded on ARWR since 2026-06-21.
The five above landed across 2 days. The other 7 were recorded on 1 other days. 7 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ARWR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 04280A100 · 2026Q2 | $47.3M | 0.03% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 04280A100 · 2026Q2 | $38.2M | 0.05% | , |
| D. E. Shaw & Co., Inc.CUSIP 04280A100 · 2026Q2 | $35.2M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 04280A100 · 2026Q2 | $26.8M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ARWR
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ARWR against its peers
ARWR's operating margin of 11.9% ranks in the 66th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | ARWR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 829M USD | 389M USD | 69 | 17 |
| Operating margin | 11.9% | -40.4% | 66 | 15 |
| Net margin | -0.2% | -40.4% | 66 | 15 |
| Return on equity | -0.3% | -21.7% | 73 | 19 |
| P / E | n/a | 32.0x | n/a | 5 |
Peers (23): IBRX, CYTK, CRNX, CAI, KYMR, PTGX, PCVX, TGTX, NUVL, PRAX, KRYS, ABVX, APGE, IONS, SYRE, BMRN, MDGL, IMVT, RYTM, ALKS, BLTE, HALO, BBIO. Left out: BCHMY (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ARWR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ARWR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ARWR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.